期刊
TRANSPLANTATION
卷 101, 期 10, 页码 2277-2287出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000001757
关键词
-
资金
- Canadian Institutes of Health Research (CIHR) through Canadian National Transplant Research Program [TFU 127880, MOP93793]
- Canadian Cancer Society Research Institute [703813]
- Canada Graduate Scholarship-Master's Award from CIHR
- BC Children's Hospital Research Institute
Cellular therapy with CD4(+)FOXP3(+) T regulatory (Treg) cells is a promising strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host disease after transfer of hematopoietic stem cells. Treg cells currently used in clinical trials are either polyclonal, donor-or antigen-specific. Aside from variations in isolation and expansion protocols, however, most therapeutic Treg cell-based products are much alike. Ongoing basic science work has provided considerable new insight into multiple facets of Treg cell biology, including their stability, homing, and functional specialization; integrating these basic science discoveries with clinical efforts will support the development of next-generation therapeutic Treg cells with enhanced efficacy. In this review, we summarize recent advances in knowledge of how Treg cells home to lymphoid and peripheral tissues, and control antibody production and tissue repair. We also discuss newly appreciated pathways that modulate context-specific Treg cell function and stability. Strategies to improve and tailor Treg cells for cell therapy to induce transplantation tolerance are highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据